… Primary endpoints of this study included assessment of no-reflow phenomenon based on
TIMI grade flow and ST-segment resolution (STR) after PPCI. Secondary endpoints were …

… the effect of intracoronary adenosine in preventing the no-reflow phenomenon, as detected
… adenosine before stenting or the control group who received the standard treatment. …

… , adenosine is not currently routinely used during PCI, but it may be used to treat no-reflow, …
The majority of the data suggested that fibrinolytic therapy as an adjunct to PCI is not useful …

… approach in treating or preventing no-reflow post-STMI might be combinational therapy. By
… Comparison of combination therapy of adenosine and nitroprusside with adenosine alone …

… for VEGF and genes encoding adenosine receptors and various ion channels can also
make one susceptible to develop microvascular dysfunction and no-reflow phenomenon.[6] …

… The role of fibrinolytic therapy is also still under study. In fact, … do not support its use as adjuvant
therapy to improve NR [48]… (B), no-reflow phenomenon refractory to the use of adenosine …

… Generally, we initially use IC nitrate or IC adenosine to resolve the phenomenon, and when
… no-reflow phenomenon, highlighting the importance of this strategy as a first-line treatment in …

… for VEGF and genes encoding adenosine receptors and various ion channels can also
make one susceptible to develop microvascular dysfunction and no-reflow phenomenon.[6] …

… Adenosine and sodium nitroprusside (SNP) are probably the most evaluated adjunctive
therapies designed to attenuate MVO and infarct size. Adenosine produces smooth muscle …

… Encouraged by positive results in animal models of reperfusion injury, the use of adenosine
as adjunctive therapy to reperfusion during STEMI was evaluated in the Acute Myocardial …